| Compound | VIP (Vasoactive Intestinal Peptide) |
|---|---|
| Category | Endogenous neuropeptide |
| Class | Neuro, Nootropic, and Cosmetic Peptides |
| Evidence tier | Clinical-stage |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
VIP (Vasoactive Intestinal Peptide) — a endogenous neuropeptide — sits in the "Clinical-stage" tier of this catalog. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
A 28-amino-acid neuropeptide with roles in smooth-muscle relaxation, circadian biology, and immune regulation. Inhaled VIP has been trialed for pulmonary hypertension; autoantibodies to VIP are studied in autoimmune contexts.
Mechanism of Action
VIP acts through VPAC1/VPAC2 receptors with potent vasodilatory and immunomodulatory effects; it is also a key neurotransmitter of the autonomic system.
Research and Evidence
Small clinical trials of inhaled VIP in pulmonary hypertension reported mixed exercise-capacity outcomes; research into VIP-autoimmunity continues. Not an approved therapy in that indication.
Safety and Side Effects
Intravenous VIP caused hypotension in studies; any systemic use is experimental.
Frequently Asked Questions
What is the evidence tier of VIP (Vasoactive Intestinal Peptide)?
VIP (Vasoactive Intestinal Peptide) is graded "Clinical-stage" on this site. This compound has completed or is undergoing formal human trials. Human safety and efficacy are being characterized, but no universal approval exists and results may still fail or be withdrawn.
Is VIP (Vasoactive Intestinal Peptide) an approved medicine?
No. Clinical-stage means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for VIP (Vasoactive Intestinal Peptide)?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — registered VIP studies. [source]
Evidence tier: Clinical-stage · Last reviewed: 2026-09-05 · Sources cited below.